Literature DB >> 18828974

Treatment of myeloma: cure vs control.

S Vincent Rajkumar1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18828974      PMCID: PMC3923461          DOI: 10.4065/83.10.1142

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


× No keyword cloud information.
  56 in total

1.  Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.

Authors:  S Vincent Rajkumar; Suzanne R Hayman; Martha Q Lacy; Angela Dispenzieri; Susan M Geyer; Brian Kabat; Steven R Zeldenrust; Shaji Kumar; Philip R Greipp; Rafael Fonseca; John A Lust; Stephen J Russell; Robert A Kyle; Thomas E Witzig; Morie A Gertz
Journal:  Blood       Date:  2005-08-23       Impact factor: 22.113

2.  Total therapy with tandem transplants for newly diagnosed multiple myeloma.

Authors:  B Barlogie; S Jagannath; K R Desikan; S Mattox; D Vesole; D Siegel; G Tricot; N Munshi; A Fassas; S Singhal; J Mehta; E Anaissie; D Dhodapkar; S Naucke; J Cromer; J Sawyer; J Epstein; D Spoon; D Ayers; B Cheson; J Crowley
Journal:  Blood       Date:  1999-01-01       Impact factor: 22.113

3.  High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial.

Authors:  J P Fermand; P Ravaud; S Chevret; M Divine; V Leblond; C Belanger; M Macro; E Pertuiset; F Dreyfus; X Mariette; C Boccacio; J C Brouet
Journal:  Blood       Date:  1998-11-01       Impact factor: 22.113

4.  Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

Authors:  Paul G Richardson; Pieter Sonneveld; Michael W Schuster; David Irwin; Edward A Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Dina Ben-Yehuda; Sagar Lonial; Hartmut Goldschmidt; Donna Reece; Jesus F San-Miguel; Joan Bladé; Mario Boccadoro; Jamie Cavenagh; William S Dalton; Anthony L Boral; Dixie L Esseltine; Jane B Porter; David Schenkein; Kenneth C Anderson
Journal:  N Engl J Med       Date:  2005-06-16       Impact factor: 91.245

5.  Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT.

Authors:  Charles Crawley; Marc Lalancette; Richard Szydlo; Maria Gilleece; Karl Peggs; Stephen Mackinnon; Gunnar Juliusson; Lucia Ahlberg; Arnon Nagler; Avichai Shimoni; Anna Sureda; Jean-Michel Boiron; Herman Einsele; Rajesh Chopra; Angelo Carella; Jamie Cavenagh; Alois Gratwohl; Frederic Garban; Axel Zander; Bo Björkstrand; Dietger Niederwieser; Gösta Gahrton; Jane F Apperley
Journal:  Blood       Date:  2005-02-24       Impact factor: 22.113

6.  Autologous stem cell transplantation for relapsed and primary refractory myeloma.

Authors:  S V Rajkumar; R Fonseca; M Q Lacy; T E Witzig; J A Lust; P R Greipp; T M Therneau; R A Kyle; M R Litzow; M A Gertz
Journal:  Bone Marrow Transplant       Date:  1999-06       Impact factor: 5.483

7.  Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma.

Authors:  B Barlogie; S Jagannath; D H Vesole; S Naucke; B Cheson; S Mattox; D Bracy; S Salmon; J Jacobson; J Crowley; G Tricot
Journal:  Blood       Date:  1997-02-01       Impact factor: 22.113

8.  High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.

Authors:  J Anthony Child; Gareth J Morgan; Faith E Davies; Roger G Owen; Susan E Bell; Kim Hawkins; Julia Brown; Mark T Drayson; Peter J Selby
Journal:  N Engl J Med       Date:  2003-05-08       Impact factor: 91.245

9.  A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.

Authors:  M Attal; J L Harousseau; A M Stoppa; J J Sotto; J G Fuzibet; J F Rossi; P Casassus; H Maisonneuve; T Facon; N Ifrah; C Payen; R Bataille
Journal:  N Engl J Med       Date:  1996-07-11       Impact factor: 91.245

10.  A phase 2 study of bortezomib in relapsed, refractory myeloma.

Authors:  Paul G Richardson; Bart Barlogie; James Berenson; Seema Singhal; Sundar Jagannath; David Irwin; S Vincent Rajkumar; Gordan Srkalovic; Melissa Alsina; Raymond Alexanian; David Siegel; Robert Z Orlowski; David Kuter; Steven A Limentani; Stephanie Lee; Teru Hideshima; Dixie-Lee Esseltine; Michael Kauffman; Julian Adams; David P Schenkein; Kenneth C Anderson
Journal:  N Engl J Med       Date:  2003-06-26       Impact factor: 91.245

View more
  26 in total

1.  Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial.

Authors:  Shaji K Kumar; Martha Q Lacy; Suzanne R Hayman; Keith Stewart; Francis K Buadi; Jacob Allred; Kristina Laumann; Philip R Greipp; John A Lust; Morie A Gertz; Steven R Zeldenrust; P Leif Bergsagel; Craig B Reeder; Thomas E Witzig; Rafael Fonseca; Stephen J Russell; Joseph R Mikhael; David Dingli; S Vincent Rajkumar; Angela Dispenzieri
Journal:  Am J Hematol       Date:  2011-05-31       Impact factor: 10.047

Review 2.  Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence.

Authors:  S Vincent Rajkumar; Robert A Kyle; Francis K Buadi
Journal:  Mayo Clin Proc       Date:  2010-10       Impact factor: 7.616

3.  Myelodysplastic syndromes--many new drugs, little therapeutic progress.

Authors:  Ayalew Tefferi
Journal:  Mayo Clin Proc       Date:  2010-09-22       Impact factor: 7.616

4.  Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management

Authors: 
Journal:  Am J Hematol       Date:  2018-08-16       Impact factor: 10.047

5.  Survivorship care guidelines for patients living with multiple myeloma: consensus statements of the International Myeloma Foundation Nurse Leadership Board.

Authors:  Elizabeth Bilotti; Beth M Faiman; Tiffany A Richards; Joseph D Tariman; Teresa S Miceli; Sandra I Rome
Journal:  Clin J Oncol Nurs       Date:  2011-08       Impact factor: 1.027

6.  [Clincal features and treatment of multiple myeloma].

Authors:  E K Mai; H Goldschmidt
Journal:  Radiologe       Date:  2014-06       Impact factor: 0.635

7.  The current status of minimal residual disease assessment in myeloma.

Authors:  S K Kumar; S V Rajkumar
Journal:  Leukemia       Date:  2014-02       Impact factor: 11.528

8.  Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management.

Authors:  S Vincent Rajkumar
Journal:  Am J Hematol       Date:  2012-01       Impact factor: 10.047

9.  Multiple myeloma: an update.

Authors:  Khalil Al-Farsi
Journal:  Oman Med J       Date:  2013-01

10.  Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines.

Authors:  Shaji K Kumar; Joseph R Mikhael; Francis K Buadi; David Dingli; Angela Dispenzieri; Rafael Fonseca; Morie A Gertz; Philip R Greipp; Suzanne R Hayman; Robert A Kyle; Martha Q Lacy; John A Lust; Craig B Reeder; Vivek Roy; Stephen J Russell; Kristen E Detweiler Short; A Keith Stewart; Thomas E Witzig; Steven R Zeldenrust; Robert J Dalton; S Vincent Rajkumar; P Leif Bergsagel
Journal:  Mayo Clin Proc       Date:  2009-12       Impact factor: 7.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.